血清 miR-98 低表达可作为非小细胞肺癌患者预后不良的生物标志物。
Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer.
机构信息
Department of Cardiothoracic Surgey Ward 12, Daqing Oil Field General Hospital, Daqing, Heilongjiang 163001, China.
Department of Gynaecology Ward 9, Daqing Oil Field General Hospital, Daqing, Heilongjiang 163001, China.
出版信息
Cancer Biomark. 2017 Sep 7;20(3):283-288. doi: 10.3233/CBM-170124.
BACKGROUND
Blood-circulating miRNAs have been reported to act as potential biomarkers in various cancers including non-small cell lung cancer (NSCLC).
OBJECTIVE
This study was to assess serum miR-98 levels in NSCLC patients and explore its potential prognostic value.
METHODS
The relative expression levels of miR-98 were detected by quantitative RT-PCR in the sera of 127 NSCLC patients and 60 healthy controls.
RESULTS
Our results showed that serum miR-98 expression was down-regulated in NSCLC patients compared with healthy controls. Receiver operating characteristic (ROC) curve analysis suggested that serum miR-98 could be used as a potential marker in the diagnosis of NSCLC. In addition, decreased serum miR-98 was positively correlated with worse TNM stage, lymph node metastasis, as well as unfavorable overall survival. Multivariate Cox regression analysis confirmed that serum miR-98 expression was an independent prognostic factor for NSCLC.
CONCLUSIONS
Therefore, serum miR-98 might be useful as a promising biomarker for prognosis prediction of NSCLC.
背景
循环血液中的 microRNA（miRNA）已被报道在多种癌症中充当潜在的生物标志物，包括非小细胞肺癌（NSCLC）。
目的
本研究旨在评估 NSCLC 患者血清 miR-98 水平，并探索其潜在的预后价值。
方法
采用实时定量 RT-PCR 法检测 127 例 NSCLC 患者和 60 例健康对照者血清中 miR-98 的相对表达水平。
结果
研究结果显示，与健康对照组相比，NSCLC 患者血清 miR-98 表达下调。受试者工作特征（ROC）曲线分析表明，血清 miR-98 可作为 NSCLC 诊断的潜在标志物。此外，血清 miR-98 降低与更差的 TNM 分期、淋巴结转移以及不良的总生存期显著相关。多因素 Cox 回归分析证实，血清 miR-98 表达是 NSCLC 的独立预后因素。
结论
因此，血清 miR-98 可能是预测 NSCLC 预后的一种很有前途的生物标志物。
Zotero 插件